10.1038/s41598-025-21975-7 68 NgoV.DuennwaldM
In summary, when added to insulin in the setting of inadequately controlled type 2 diabetes, oral semaglutide was superior to placebo at improving glycemic control and reducing body weight over 26 weeks, with significant differences also seen at 52 weeks, and with no increase in the risk of hypoglycemia
Retatrutide targets three hormone receptorsGLP-1, GIP, and glucagonwhile semaglutide only targets GLP-1
After the first month, the dosage is usually increased to 0.5 mg once weekly
Why It Matters for Patients Targeting stubborn fat: Belly fat and liver fat are among the most harmful types of fat for long-term health
Phase 2 Liver Fat (MASLD/MASH Substudy) Study: Published by Sanyal et al